BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1810444)

  • 1. Interferons in the treatment of malignancies.
    Kardamakis D
    In Vivo; 1991; 5(6):589-97. PubMed ID: 1810444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological monitoring and clinical trials of biological response modifiers.
    Baseler MW; Urba WJ
    Cancer Chemother Biol Response Modif; 1991; 12():231-50. PubMed ID: 1931445
    [No Abstract]   [Full Text] [Related]  

  • 3. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
    Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
    Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alpha interferons--new therapeutic modalities].
    Bajcetić M; Zigon N; Samardzić R; Beleslin DB
    Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of the ATP-cell viability assay for assessment of biologic response modifiers in gynecologic cancer.
    Angioli R; Sevin BU
    Contrib Gynecol Obstet; 1994; 19():166-78. PubMed ID: 7995048
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Makower D; Wadler S
    Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta.
    Brockmeyer NH; Barthel B; Mertins L; Goos M
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):309-11. PubMed ID: 9660037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of multiple sclerosis with interferons].
    Nogales-Gaete J; Arriagada C
    Rev Med Chil; 1996 May; 124(5):597-604. PubMed ID: 9035514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in cytokine production of breast cancer patients treated with interferons.
    Barak V; Kalickman I; Nisman B; Farbstein H; Fridlender ZG; Baider L; Kaplan A; Stephanos S; Peretz T
    Cytokine; 1998 Dec; 10(12):977-83. PubMed ID: 10049522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The interferon system. A review of biological principles and clinical uses].
    Schneider FJ
    Z Gesamte Inn Med; 1986 Nov; 41(22):613-8. PubMed ID: 2436387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
    Lindner DJ; Borden EC; Kalvakolanu DV
    Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of interferons in the treatment of malignant neoplasms.
    Murren JR; Buzaid AC
    Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon-alpha, beta, gamma].
    Imanishi J
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2853-8. PubMed ID: 7993128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferons in the management of viral hepatitis.
    Zein NN
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):229-41. PubMed ID: 10068057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation.
    Dash S; Prabhu R; Hazari S; Bastian F; Garry R; Zou W; Haque S; Joshi V; Regenstein FG; Thung SN
    Liver Int; 2005 Jun; 25(3):580-94. PubMed ID: 15910496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferons. New additions and indications for use.
    Stadler R; Ruszczak Z
    Dermatol Clin; 1993 Jan; 11(1):187-99. PubMed ID: 7679614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of combination biotherapy studies: future goals and challenges.
    Gilewski TA; Golomb HM
    Semin Oncol; 1990 Feb; 17(1 Suppl 1):3-10; discussion 38-41. PubMed ID: 1689077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experiences with interferon-alpha and interferon-gamma.
    Steinmann GG; Rosenkaimer F; Leitz G
    Int Rev Exp Pathol; 1993; 34 Pt B():193-207. PubMed ID: 8458713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.